Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks

Timothy J. Craig, Againdra K. Bewtra, David Hurewitz, Robyn Levy, Gerti Janss, Kraig W. Jacobson, Flint Packer, Jonathan A. Bernstein, Mikhail A. Rojavin, Thomas Machnig, Heinz Otto Keinecke, Richard L. Wasserman

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Placebo-controlled studies established the efficacy of replacement therapy with C1 esterase inhibitor (C1-INH) concentrate for treating single acute hereditary angioedema (HAE) attacks, but only limited data from prospective studies are available on repeated treatment of successive HAE attacks. This study evaluates the association between repeated treatments with 20 U/kg of C1-INH concentrate (Berinert; CSL Behring, Marburg, Germany) for HAE attacks at any body location and treatment response. In a post hoc analysis of an open-label extension study (International Multicenter Prospective Angioedema C1-INH Trial [I.M.P.A.C.T.2]), the association between repeated treatment with C1-INH and times to onset of symptom relief and complete resolution of HAE symptoms was assessed in patients who were treated for at least 15 attacks by linear regression on the ordinal attack number. Eighteen patients received C1-INH concentrate for at least 15 HAE attacks over a mean duration of 34 months. Demographic and baseline characteristics of these patients were similar to those of all patients in the study. The distribution of body locations and the intensity of HAE attacks were similar for each of the first 15 attacks and subsequent attacks. The extent of previous use of C1-INH concentrate had no effect on the time to onset of symptom relief, the time to complete resolution of HAE symptoms, or the time between attacks treated with C1-INH concentrate; the median of individual linear regression coefficients was not statistically significantly different from 0. Treatment with 20 U/kg of C1-INH concentrate provided consistent treatment response in patients treated for multiple successive HAE attacks at any body location. (Clinicaltrials.gov identifier: NCT00292981).

Original languageEnglish
Pages (from-to)354-361
Number of pages8
JournalAllergy and Asthma Proceedings
Volume33
Issue number4
DOIs
StatePublished - Jul 2012

Fingerprint

Complement C1 Inhibitor Protein
Hereditary Angioedemas
Therapeutics
Linear Models
Angioedema
Multicenter Studies
Germany
Placebos
Demography
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. / Craig, Timothy J.; Bewtra, Againdra K.; Hurewitz, David; Levy, Robyn; Janss, Gerti; Jacobson, Kraig W.; Packer, Flint; Bernstein, Jonathan A.; Rojavin, Mikhail A.; Machnig, Thomas; Keinecke, Heinz Otto; Wasserman, Richard L.

In: Allergy and Asthma Proceedings, Vol. 33, No. 4, 07.2012, p. 354-361.

Research output: Contribution to journalArticle

Craig, TJ, Bewtra, AK, Hurewitz, D, Levy, R, Janss, G, Jacobson, KW, Packer, F, Bernstein, JA, Rojavin, MA, Machnig, T, Keinecke, HO & Wasserman, RL 2012, 'Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks', Allergy and Asthma Proceedings, vol. 33, no. 4, pp. 354-361. https://doi.org/10.2500/aap.2012.33.3589
Craig, Timothy J. ; Bewtra, Againdra K. ; Hurewitz, David ; Levy, Robyn ; Janss, Gerti ; Jacobson, Kraig W. ; Packer, Flint ; Bernstein, Jonathan A. ; Rojavin, Mikhail A. ; Machnig, Thomas ; Keinecke, Heinz Otto ; Wasserman, Richard L. / Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. In: Allergy and Asthma Proceedings. 2012 ; Vol. 33, No. 4. pp. 354-361.
@article{fdba766901ca493380edaca5115ff150,
title = "Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks",
abstract = "Placebo-controlled studies established the efficacy of replacement therapy with C1 esterase inhibitor (C1-INH) concentrate for treating single acute hereditary angioedema (HAE) attacks, but only limited data from prospective studies are available on repeated treatment of successive HAE attacks. This study evaluates the association between repeated treatments with 20 U/kg of C1-INH concentrate (Berinert; CSL Behring, Marburg, Germany) for HAE attacks at any body location and treatment response. In a post hoc analysis of an open-label extension study (International Multicenter Prospective Angioedema C1-INH Trial [I.M.P.A.C.T.2]), the association between repeated treatment with C1-INH and times to onset of symptom relief and complete resolution of HAE symptoms was assessed in patients who were treated for at least 15 attacks by linear regression on the ordinal attack number. Eighteen patients received C1-INH concentrate for at least 15 HAE attacks over a mean duration of 34 months. Demographic and baseline characteristics of these patients were similar to those of all patients in the study. The distribution of body locations and the intensity of HAE attacks were similar for each of the first 15 attacks and subsequent attacks. The extent of previous use of C1-INH concentrate had no effect on the time to onset of symptom relief, the time to complete resolution of HAE symptoms, or the time between attacks treated with C1-INH concentrate; the median of individual linear regression coefficients was not statistically significantly different from 0. Treatment with 20 U/kg of C1-INH concentrate provided consistent treatment response in patients treated for multiple successive HAE attacks at any body location. (Clinicaltrials.gov identifier: NCT00292981).",
author = "Craig, {Timothy J.} and Bewtra, {Againdra K.} and David Hurewitz and Robyn Levy and Gerti Janss and Jacobson, {Kraig W.} and Flint Packer and Bernstein, {Jonathan A.} and Rojavin, {Mikhail A.} and Thomas Machnig and Keinecke, {Heinz Otto} and Wasserman, {Richard L.}",
year = "2012",
month = "7",
doi = "10.2500/aap.2012.33.3589",
language = "English",
volume = "33",
pages = "354--361",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks

AU - Craig, Timothy J.

AU - Bewtra, Againdra K.

AU - Hurewitz, David

AU - Levy, Robyn

AU - Janss, Gerti

AU - Jacobson, Kraig W.

AU - Packer, Flint

AU - Bernstein, Jonathan A.

AU - Rojavin, Mikhail A.

AU - Machnig, Thomas

AU - Keinecke, Heinz Otto

AU - Wasserman, Richard L.

PY - 2012/7

Y1 - 2012/7

N2 - Placebo-controlled studies established the efficacy of replacement therapy with C1 esterase inhibitor (C1-INH) concentrate for treating single acute hereditary angioedema (HAE) attacks, but only limited data from prospective studies are available on repeated treatment of successive HAE attacks. This study evaluates the association between repeated treatments with 20 U/kg of C1-INH concentrate (Berinert; CSL Behring, Marburg, Germany) for HAE attacks at any body location and treatment response. In a post hoc analysis of an open-label extension study (International Multicenter Prospective Angioedema C1-INH Trial [I.M.P.A.C.T.2]), the association between repeated treatment with C1-INH and times to onset of symptom relief and complete resolution of HAE symptoms was assessed in patients who were treated for at least 15 attacks by linear regression on the ordinal attack number. Eighteen patients received C1-INH concentrate for at least 15 HAE attacks over a mean duration of 34 months. Demographic and baseline characteristics of these patients were similar to those of all patients in the study. The distribution of body locations and the intensity of HAE attacks were similar for each of the first 15 attacks and subsequent attacks. The extent of previous use of C1-INH concentrate had no effect on the time to onset of symptom relief, the time to complete resolution of HAE symptoms, or the time between attacks treated with C1-INH concentrate; the median of individual linear regression coefficients was not statistically significantly different from 0. Treatment with 20 U/kg of C1-INH concentrate provided consistent treatment response in patients treated for multiple successive HAE attacks at any body location. (Clinicaltrials.gov identifier: NCT00292981).

AB - Placebo-controlled studies established the efficacy of replacement therapy with C1 esterase inhibitor (C1-INH) concentrate for treating single acute hereditary angioedema (HAE) attacks, but only limited data from prospective studies are available on repeated treatment of successive HAE attacks. This study evaluates the association between repeated treatments with 20 U/kg of C1-INH concentrate (Berinert; CSL Behring, Marburg, Germany) for HAE attacks at any body location and treatment response. In a post hoc analysis of an open-label extension study (International Multicenter Prospective Angioedema C1-INH Trial [I.M.P.A.C.T.2]), the association between repeated treatment with C1-INH and times to onset of symptom relief and complete resolution of HAE symptoms was assessed in patients who were treated for at least 15 attacks by linear regression on the ordinal attack number. Eighteen patients received C1-INH concentrate for at least 15 HAE attacks over a mean duration of 34 months. Demographic and baseline characteristics of these patients were similar to those of all patients in the study. The distribution of body locations and the intensity of HAE attacks were similar for each of the first 15 attacks and subsequent attacks. The extent of previous use of C1-INH concentrate had no effect on the time to onset of symptom relief, the time to complete resolution of HAE symptoms, or the time between attacks treated with C1-INH concentrate; the median of individual linear regression coefficients was not statistically significantly different from 0. Treatment with 20 U/kg of C1-INH concentrate provided consistent treatment response in patients treated for multiple successive HAE attacks at any body location. (Clinicaltrials.gov identifier: NCT00292981).

UR - http://www.scopus.com/inward/record.url?scp=84864773763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864773763&partnerID=8YFLogxK

U2 - 10.2500/aap.2012.33.3589

DO - 10.2500/aap.2012.33.3589

M3 - Article

C2 - 22856636

AN - SCOPUS:84864773763

VL - 33

SP - 354

EP - 361

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 4

ER -